Lester Nave, MD
Family Medicine · Sanford, NCNPI 1407857212
Payments from drug & device makers
Across 242 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Amgen$344
- Boehringer Ingelheim$229
- Lilly USA, LLC$204
- Novartis$187
- Bayer$177
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,968100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 85 | $1,432 |
| Amgen(2 entities) | 27 | $344 |
| Boehringer Ingelheim | 11 | $229 |
| Lilly USA, LLC | 16 | $204 |
| Novartis | 12 | $187 |
| Bayer | 11 | $177 |
| AbbVie | 10 | $150 |
| GSK | 7 | $149 |
| Daiichi Sankyo Inc. | 6 | $121 |
| Amarin Pharma, Inc. | 8 | $113 |
| Otsuka America Pharmaceutical, Inc. | 5 | $95 |
| Sanofi-aventis U.S. LLC | 5 | $87 |
| Merck | 5 | $76 |
| Idorsia Pharmaceuticals US Inc | 4 | $59 |
| Exact Sciences | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Shield Therapeutics Inc | 1 | $43 |
| AstraZeneca | 2 | $37 |
| Abbott | 1 | $31 |
| Pfizer | 2 | $30 |
| Agios Pharmaceuticals, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $19 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Cranial Technologies, Inc | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Kaleo, Inc. | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $13 |
| IBSA Pharma Inc. | 1 | $13 |
| Agile Therapeutics, Inc. | 1 | $13 |
| Tris Pharma Inc | 1 | $11 |
How this compares
$3,968 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 195 | $203,650 |
| OzempicSemaglutide | 112 | $144,354 |
| EliquisApixaban | 107 | $104,178 |
| MounjaroTirzepatide | 57 | $68,665 |
| JanuviaSitagliptin Phosphate | 66 | $50,186 |
| Repatha SureclickEvolocumab | 50 | $34,758 |
| XareltoRivaroxaban | 28 | $28,637 |
| EntrestoSacubitril/Valsartan | 25 | $24,053 |
| RybelsusSemaglutide | 19 | $22,021 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $21,742 |
| TrulicityDulaglutide | 11 | $15,690 |
| VyvanseLisdexamfetamine Dimesylate | 23 | $14,710 |
| Spiriva RespimatTiotropium Bromide | 11 | $10,621 |
| MyrbetriqMirabegron | 17 | $9,678 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $8,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $229 | $214,271206 claims |
| Novo NordiskOzempic, Rybelsus | $1,432 | $166,375131 claims |
| PfizerEliquis | $30 | $104,178107 claims |
| Lilly USA, LLCMounjaro, Trulicity | $204 | $84,35568 claims |
| MerckJanuvia | $76 | $50,18666 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $149 | $32,17860 claims |
| NovartisEntresto | $187 | $24,05325 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $9,67817 claims |
| AbbVieSynthroid | $150 | $2,21127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Sanford
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.